Loading viewer...
conference
Format: PDF conference
Insmed presented at the J.P. Morgan Healthcare Conference in January 2024, discussing its rare disease pipeline including ARIKAYCE (amikacin liposome inhalation suspension) for nontuberculous mycobacteria infections and clinical-stage programs brensocatib and TPIP. The company addresses regulatory approval strategies, commercialization challenges, and market adoption risks for its approved and investigational therapies.
investor_presentation
46 Pages
conference
67 Pages
Central Pattana Public Company
Ichor Holdings 2023 B. Riley Securities Conference
conferenceconference
20 Pages
Ichor Holdings, Ltd.